Agonists and Antagonists
- CP 94253 hydrochloride [orb180853]
[845861-39-4]
293.7918
C15N3OCLH20
Cl.CCCOC1C=CC2=C(C(C3CCNCC=3)=CN2)N=1
10 mm, 100 mg, 250 mg, 1000 mg - CM346 [orb181414]
[173352-21-1]
307.41114
C15H21N3O2S
CCOC1=CC=C2C(N=C(SCCN3CCOCC3)N2)=C1
100 mg, 250 mg, 1000 mg - LuAE58054 [orb181400]
[467459-31-0]
398.36966
C20H19N2OF5
FC1=CC(NC=C2CCNCC3=CC(OCC(F)(C(F)F)F)=CC=C3)=C2C=C1
100 mg, 250 mg, 1000 mg - NVP-AAM077 [orb181393]
[459836-30-7]
454.21
C17H15BrN3Na4O6P
[O-]C1=NC2C(=CC=CC=2N=C1[O-])C(N[C@H](C)C1C=CC(Br)=CC=1)P(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+]
100 mg, 250 mg, 1000 mg - GW-4064 [orb181383]
[278779-30-9]
542.8376
C28H22CL3NO4
ClC1C([H])=C([H])C([H])=C(C=1C1C(C([H])([H])OC2C([H])=C([H])C(/C(/[H])=C(\[H])/C3C([H])=C([H])C([H])=C(C(=O)O[H])C=3[H])=C(C=2[H])Cl)=C(C([H])(C([H])([H])[H])C([H])([H])[H])ON=1)Cl
10 mm, 100 mg, 250 mg, 1000 mg - 1 imageBQ-788 [orb181359]
[156161-89-6]
663.77988
C34H50N5NAO7
[Na+].CCCC[C@@H](N(C([C@@H](NC(N1[C@H](C)CCC[C@@H]1C)=O)CC(C)(C)C)=O)C([C@@H](CC1=CN(C(OC)=O)C2=CC=CC=C12)N)=O)C([O-])=O
100 mg, 250 mg, 1000 mg -
- TCS 1102 [orb181332]
[916141-36-1]
470.59
C27H26N4O2S
O=C([C@H]1N(C(CSC2=NC3=CC=CC=C3N2C)=O)CCC1)NC4=CC=CC=C4C5=CC=CC=C5
10 mm, 100 mg, 250 mg, 1000 mg - Tasosartan [orb181331]
[145733-36-4]
411.45914
C23H21N7O
O=C1N(CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)C(N=C5C)=C(C(C)=N5)CC1
100 mg, 250 mg, 1000 mg - Siramesine-hydrochloride [orb181321]
[224177-60-0]
454.5894
C30H31FN2O
FC1=CC=C(N2C=C(CCCCN3CCC4(CC3)OCC5=C4C=CC=C5)C6=C2C=CC=C6)C=C1.Cl
10 mm, 100 mg, 250 mg, 1000 mg - Siramesine [orb181320]
[147817-50-3]
454.58
C30H31FN2O
C1(CCN(CCCCC2C3=C(N(C4=CC=C(F)C=C4)C=2)C=CC=C3)CC1)1C2=C(C=CC=C2)CO1
10 mm, 100 mg, 250 mg, 1000 mg
